Assembly Biosciences, Inc. (ASMB)
34.07
-0.73
(-2.10%)
USD |
NASDAQ |
Aug 28, 16:00
34.00
-0.07
(-0.21%)
After-Hours: 20:00
Assembly Biosciences EPS Diluted (Quarterly) : -0.2046 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2046 |
| March 31, 2026 | -0.5372 |
| December 31, 2025 | 1.393 |
| September 30, 2025 | -0.7249 |
| June 30, 2025 | -1.332 |
| March 31, 2025 | -1.175 |
| December 31, 2024 | -1.570 |
| September 30, 2024 | -1.514 |
| June 30, 2024 | -1.976 |
| March 31, 2024 | -1.655 |
| December 31, 2023 | -1.999 |
| September 30, 2023 | -3.292 |
| June 30, 2023 | -3.880 |
| March 31, 2023 | -4.458 |
| December 31, 2022 | -5.508 |
| September 30, 2022 | -5.733 |
| June 30, 2022 | -6.078 |
| March 31, 2022 | -5.758 |
| December 31, 2021 | -15.03 |
| September 30, 2021 | -4.951 |
| June 30, 2021 | -6.604 |
| March 31, 2021 | -8.226 |
| December 31, 2020 | -13.90 |
| September 30, 2020 | -1.132 |
| June 30, 2020 | 2.339 |
| Date | Value |
|---|---|
| March 31, 2020 | -9.118 |
| December 31, 2019 | -11.88 |
| September 30, 2019 | -11.58 |
| June 30, 2019 | -8.626 |
| March 31, 2019 | -12.65 |
| December 31, 2018 | -12.31 |
| September 30, 2018 | -10.39 |
| June 30, 2018 | -15.60 |
| March 31, 2018 | -9.60 |
| December 31, 2017 | -1.92 |
| September 30, 2017 | -8.52 |
| June 30, 2017 | -9.36 |
| March 31, 2017 | -9.72 |
| December 31, 2016 | -8.04 |
| September 30, 2016 | -8.04 |
| June 30, 2016 | -7.08 |
| March 31, 2016 | -7.68 |
| December 31, 2015 | -5.398 |
| September 30, 2015 | -4.56 |
| June 30, 2015 | -4.92 |
| March 31, 2015 | -7.68 |
| December 31, 2014 | -7.004 |
| September 30, 2014 | -15.96 |
| June 30, 2014 | -31.20 |
| March 31, 2014 | -10.80 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -8.444 |
| BridgeBio Pharma, Inc. | -0.7775 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.857M |
| Revenue (Quarterly) | 13.37M |
| Total Expenses (Quarterly) | 17.23M |
| Enterprise Value | 358.29M |
| Gross Profit Margin (Quarterly) | 99.85% |
| Profit Margin (Quarterly) | -28.84% |
| Earnings Yield | -0.22% |
| Normalized Earnings Yield | -0.2157 |